Large Scale Clinical Trial Finds Omega 3 Supplements Reduce Major Cardiovascular Risks by 43 Percent in Dialysis Patients

A major Monash University study finds high-dose omega-3 supplements significantly reduce strokes and heart attacks in patients undergoing hemodialysis.

By: AXL Media

Published: Mar 11, 2026, 10:56 AM EDT

Source: Information for this report was sourced from Monash University

A Breakthrough in Cardiovascular Protection for Kidney Patients

Patients undergoing dialysis for kidney failure face some of the highest cardiovascular risks in modern medicine, yet effective preventative therapies have historically remained elusive. A major international study, known as the PISCES trial, has identified a potent and accessible intervention that could reshape standard care for this vulnerable demographic. Researchers discovered that a daily four-gram dose of fish oil significantly bolsters heart health in patients receiving hemodialysis. The results are particularly notable because they provide a successful outcome in a clinical field that has frequently seen promising treatments fail to deliver measurable benefits during large-scale testing.

Substantial Reductions in Life Threatening Vascular Events

The primary finding of the research is a dramatic 43 percent decrease in the rate of major cardiovascular complications among participants taking the supplement. This category of serious health events includes not only heart attacks and strokes but also cardiac death and amputations necessitated by vascular disease. By utilizing a high concentration of the omega,3 fatty acids EPA and DHA, the treatment targeted specific deficiencies commonly found in the dialysis population. The sheer magnitude of the benefit observed suggests that restoring these fatty acid levels may be a critical missing component in current kidney failure management strategies.

The Targeted Impact of EPA and DHA Levels

According to Adjunct Professor Kevan Polkinghorne, a leading nephrologist at Monash Health, the success of the trial may be linked to the uniquely low baseline levels of essential fatty acids in these patients. Compared to the general public, individuals on dialysis typically possess much lower concentrations of EPA and DHA, which are vital for maintaining vascular integrity and reducing inflammation. By providing a controlled daily intake of four grams of fish oil, the trial effectively addressed this nutritional gap. Professor Polkinghorne noted that while many cardiovascular trials in this field have returned negative results, the PISCES trial offers a rare and significant confirmation of therapeutic value.